Dermata Therapeutics (DRMA) Q2 2024 earnings summary

Executive summary

• Focused on developing DMT310 (acne, psoriasis, rosacea) and DMT410 (aesthetic/medical skin conditions) using proprietary Spongilla technology; no commercialized products or revenue to date.

• Over 50% of patients enrolled in the DMT310 Phase 3 STAR-1 acne trial as of July 2024; topline results expected Q1 2025.

• Ongoing partnership discussions for DMT410, targeting topical delivery of botulinum toxin for skin conditions.

• Net loss of $2.8M for Q2 2024, up from $1.7M in Q2 2023; six-month net loss $6.0M vs. $3.9M prior year.

• Raised $2.3M in net proceeds from a financing round completed in Q2 2024.

Financial highlights

• Q2 2024 research and development expenses rose to $2.0M from $0.8M year-over-year, driven by STAR-1 trial costs.

• General and administrative expenses stable at $0.9M for Q2 2024; six-month G&A up $0.5M to $2.5M.

• Cash and cash equivalents at $4.9M as of June 30, 2024, down from $7.4M at year-end 2023; accumulated deficit $59.4M.

• Cash used in operations was $4.8M for the first half of 2024; cash runway expected into Q4 2024.

• Net loss per share (basic and diluted) for Q2 2024: $(4.18); weighted-average shares outstanding for Q2 2024: 676,567.

Outlook and guidance

• Cash expected to fund operations into Q4 2024; additional capital required to complete Phase 3 trials and continue development.

• Topline results from the DMT310 STAR-1 trial anticipated in Q1 2025; plans to complete enrollment in H2 2024.

• Plans to seek further funding via equity, debt, or collaborations; substantial doubt exists about ability to continue as a going concern without new capital.

• Focus remains on DMT310 clinical development and potential commercialization, with DMT410 partnership discussions ongoing.